ReviewWorld journal of oncology2026
Magnitude of Survival Benefit Associated With Tyrosine Kinase Inhibitors in Advanced Thyroid Carcinoma: A Systematic Review and Meta-Analysis Incorporating Updated Long-Term Evidence From SELECT (Lenvatinib) and COSMIC-311 (Cabozantinib) Trials.
Review in World journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced thyroid carcinoma. However, newer agents and updated long-term evidence from pivotal trials have not been comprehensively synthesized. This systematic review and meta-analysis integrates recent randomized evidence, including donafenib and nintedanib, with qualitative synthesis of updated SELECT (lenvatinib) and COSMIC-311 (cabozantinib) analyses, alongside separate quantitative evaluations of placebo-controlled and dose-comparison trials. Methods: PubMed/MEDLINE, Embase, Cochrane CENTRAL, Google Scholar, and reference lists were systematically searched for randomized controlled trials evaluating TKIs in advanced thyroid carcinoma. Eighteen studies were included in the systematic review, of which 14 publications contributed to the meta-analysis. Updated SELECT and COSMIC-311 analyses were synthesized qualitatively to avoid duplication of patient populations. For trials reporting progression-free survival (PFS) and overall survival (OS) in separate publications, the most appropriate publication was selected for each outcome, resulting in risk-of-bias assessment of 13 unique randomized trials using the Cochrane RoB 2 tool. Random-effects meta-analyses were performed using SAS version 9.4. Results: Thirteen randomized controlled trials involving 2,671 patients were quantitatively analyzed. Compared with placebo, TKIs significantly improved PFS (hazard ratio (HR) = 0.36; 95% confidence interval (CI), 0.26-0.50; P < 0.001), reducing the risk of disease progression or death by approximately 64%, although heterogeneity was substantial (I Conclusions: TKIs significantly improve PFS and OS in advanced thyroid carcinoma, supporting their role in contemporary clinical management. Lenvatinib demonstrated the greatest efficacy, while updated long-term evidence reinforced the durable benefits of lenvatinib and cabozantinib. Although placebo-controlled trials consistently favored TKIs, dose-comparison trials did not demonstrate superiority of higher-dose regimens. Further randomized studies with longer follow-up and biomarker-guided treatment strategies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.